Know Cancer

forgot password

Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/Phase 2
18 Years
75 Years
Not Enrolling
Neoplasm, Hepatocellular Carcinoma

Thank you

Trial Information

Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC)

The primary objectives of this study are:

- To evaluate any objective tumor responses to PEG-BCT-100 in HCC patients receiving
weekly doses of PEG-BCT-100 alone.

- To perform PK and PD analysis

- To measure Quality of Life of the patients

Secondary objectives of this study are:

- To define any toxicity associated with the metabolic and cellular alterations of ADD
relative to dose and PK of PEG-BCT-100 (rhArgIpeg5000).

- To confirm the safety and anti-tumor activity of PEG-BCT-100 at the preferred dose
(1600U/kg) in 50 patients (at least 18 evaluable subjects) with advanced HCC.

- To measure duration of response including Overall Survival and Time to Progression

Inclusion Criteria:

- Confirmed diagnosis of HCC according to the European Association for the Study of the
Liver criteria

- Known underlying HCC etiology specified by hepatitis B, hepatitis C, post alcoholic
cirrhosis, or other

- HCC lesion(s) which are not resectable and which are measurable by C-T scan

- Progression of or non-response of HCC lesions after treatments which are considered
best standard of care - surgical resection, radiofrequency ablation,

- No cancer treatment or surgery within the prior 4 weeks, either chemotherapy,
targeted biologic or enzymes, either approved or investigational;

- Males or females from 18 to 75 years-old, inclusive;

- Ability and willingness to provide written informed consent;

- Karnofsky performance status of 80% or above and expected survival of more than 12
weeks; and,

- Negative urine pregnancy test, if female, and willingness to use an effective method
of contraception during the entire study period

- No cognitive impairment

- Ability to understand and read Chinese

Exclusion Criteria:

- Advancing liver failure indicated by uncontrolled ascites, pleural effusions,
encephalopathy, or a Child-Pugh score of C

- Significant hepatic, renal or bone marrow dysfunction indicated by total bilirubin
>40 ┬Ámol/L, evidence of bile duct obstruction, serum albumin <30 g/L, serum SGOT >5 x
upper limit of normal, ANC <1.0 x 10^9/L, platelets <100 x 10^9/L, or INR >2.0

- Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA)
Class III or IV, VEF <50% by echo or MUGA, or a history of myocardial infarction
within the past 6 months, significant unstable arrhythmia or evidence of ischemia on

- Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree
to use adequate contraception (hormonal or barrier method of birth control or
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately.

- Significant active infection including HIV requiring oral or parenteral
anti-infective therapies;

- Use of investigational drug(s) within 4 weeks of enrollment; or,

- Prior treatment with arginine depleting agent.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Tumor response

Outcome Description:

Tumor response endpoints include(a)Objective response for each patient evaluated by RECIST, (b)Modified RECIST criteria will be used as secondary reference, (c) The proportion of patients achieving a partial response or complete response (d) The proportion of patients reporting disease progression by RECIST and the times to progression (e)Serial changes in plasma AFP levels after doses of PEG-BCT-100 and (f)Change in relevant viral serology from baseline to end-of-study

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Ronnie TP Poon, Prof

Investigator Role:

Principal Investigator

Investigator Affiliation:

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong


Hong Kong: Department of Health

Study ID:




Start Date:

March 2010

Completion Date:

February 2012

Related Keywords:

  • Neoplasm
  • Hepatocellular Carcinoma
  • Neoplasm
  • Hepatocellular Carcinoma
  • Neoplasms
  • Carcinoma
  • Carcinoma, Hepatocellular